Evaluation of Clinical and Economic Impact of Pharmacogenomics Testing in Taxanes-based Therapy

Since Taxol isolation from yews (Taxus brevifolia) in 1971, taxanes showed a remarkable anti-cancer activity1. Paclitaxel and docetaxel, the first two members of the taxanes family, are widely used as firstor second-line therapy (alone or in combination regimens), to treat different tumors including refractory or metastatic ones2. Although these microtubule-stabilizing drugs are very active agents3, it is not rare to develop adverse effects, especially in the form of hematologic (febrile neutropenia),